-
Implementing an anti-bullying culture in cardiology Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-08-10 Pamela S. Douglas
Bullying is common in cardiology and can have substantial adverse effects. However, bullying can be addressed by substantive leadership, organizational and individual efforts to build an inclusive and respectful culture.
-
Age-related loss of Y chromosome in leukocytes linked to cardiac fibrosis Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-08-08 Irene Fernández-Ruiz
Haematopoietic mosaic loss of the Y chromosome, a phenomenon that frequently occurs with age, directly contributes to cardiac fibrosis and dysfunction.
-
Sulfide regulation of cardiovascular function in health and disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-08-05 Gopi K. Kolluru, Rodney E. Shackelford, Xinggui Shen, Paari Dominic, Christopher G. Kevil
-
Pregnancy among cardiologists: challenges and recommendations Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-08-02 Inbar Raber, Amy A. Sarma
Childbearing cardiologists face a number of challenges before, during and after pregnancy, including radiation concerns, infertility, pregnancy-related complications, and inadequate parental leave and return-to-work structures. Institutions can promote an equitable work environment by creating policies to mitigate these challenges.
-
AIMing 2 treat atherosclerosis Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-26 Oliver Soehnlein, Alan R. Tall
-
Macrophages and neutrophils modulate arrhythmia risk after myocardial infarction Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-25 Gregory B. Lim
In a new mouse model of spontaneous ventricular tachycardia after myocardial infarction, cardiac neutrophils increased the likelihood of arrhythmia, whereas cardiac macrophages protected against arrhythmia.
-
Circular RNA prevents doxorubicin-induced cardiotoxicity Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-22 Gregory B. Lim
Overexpression of a circular RNA derived from the gene encoding the insulin receptor (Circ-INSR) prevents the development of cardiac dysfunction that occurs in response to anti-cancer therapy with doxorubicin.
-
Mechanisms and consequences of endothelial cell senescence Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-19 Samuel I. Bloom, Md Torikul Islam, Lisa A. Lesniewski, Anthony J. Donato
-
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-15 Francesco Violi, Vittoria Cammisotto, Simona Bartimoccia, Pasquale Pignatelli, Roberto Carnevale, Cristina Nocella
-
Glucocorticoid receptor inhibition promotes cardiac repair after MI Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-13 Irene Fernández-Ruiz
Transient inhibition of the glucocorticoid receptor promotes cardiomyocyte proliferation and heart regeneration after myocardial infarction in the adult mouse heart.
-
Guidelines to lower intake of added sugar are necessary and justified Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-13 Kimber L. Stanhope
The lowering of dietary recommendations for the consumption of free or added sugar from 25% to 10% of daily calories has been criticized as being based on low-quality scientific evidence, ill-informed opinions and over-extrapolation of results from studies on sugar-sweetened beverages. This Comment rebuts these criticisms.
-
Meteorin-like protein repairs the ischaemic heart via receptor KIT in endothelial cells Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-11 Karina Huynh
Meteorin-like protein acts on endothelial cells through the receptor KIT to promote angiogenesis and reduce scar formation after myocardial infarction.
-
Single-cell profiles of CHD and CM Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-11 Karina Huynh
Two new papers describe the transcriptional programmes of congenital heart disease and dilated and hypertrophic cardiomyopathy assessed using single-nucleus RNA-sequencing technologies.
-
Modulating serine biosynthesis for the treatment of dilated cardiomyopathy Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-08 Irene Fernández-Ruiz
Activating the serine biosynthesis pathway might be a potential strategy for the treatment of dilated cardiomyopathy, according to a phenotypic screening study.
-
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-04 Xuexian Fang, Hossein Ardehali, Junxia Min, Fudi Wang
-
Iron deficiency and supplementation therapy in heart failure Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-04 Pedro Moliner, Josep Comin-Colet
More than 50% of patients with chronic heart failure present with iron deficiency, which is associated with reduced quality of life and worse prognosis. Intravenous iron supplementation therapy has been shown to improve clinical outcomes in these patients.
-
Very high HDL-C levels are associated with higher mortality in patients with CAD Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-30 Irene Fernández-Ruiz
High plasma levels of HDL cholesterol have been shown to be associated with a lower risk of cardiovascular disease. However, paradoxically, very high HDL-cholesterol levels are associated with increased mortality in patients with coronary artery disease, according to a new study.
-
Piezo1 senses pressure overload and initiates cardiac hypertrophy Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-29 Gregory B. Lim
The stretch-activated, calcium-permeable Piezo1 channel is the mechanosensor that transduces cardiomyocyte stretch into the biochemical signalling pathway that leads to cardiac hypertrophy in mice.
-
Human susceptibility to coronary artery disease: lessons from chimpanzee resilience Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-29 Gemma A. Figtree, Jason C. Kovacic, Helen M. McGuire
-
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-28 Gregory B. Lim
Adding remnant cholesterol levels to traditional risk scores for ischaemic heart disease and myocardial infarction improves the accuracy of individual risk stratification.
-
Gene therapy for Brugada syndrome Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-28 Karina Huynh
Gene therapy targeting the protein trafficking regulator MOG1 successfully reversed clinical features of Brugada syndrome in a knock-in mouse model.
-
Mentorship in cardiology: building the mentoring relationship Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-27 Martha Gulati, Priya Kohli
-
The cardiac parasympathetic system has two parallel circuits Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-27 Irene Fernández-Ruiz
The cardiac parasympathetic nervous system is composed of two parallel circuits with distinct functions: one selectively controls cardiac function and another coordinates cardiac and pulmonary function.
-
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-20 Tian-Yuan Xiong, Walid Ben Ali, Yuan Feng, Kentaro Hayashida, Hasan Jilaihawi, Azeem Latib, Michael Kang-Yin Lee, Martin B. Leon, Raj R. Makkar, Thomas Modine, Christoph Naber, Yong Peng, Nicolo Piazza, Michael J. Reardon, Simon Redwood, Ashok Seth, Lars Sondergaard, Edgar Tay, Didier Tchetche, Wei-Hsian Yin, Mao Chen, Bernard Prendergast, Darren Mylotte
-
Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-13 Milton Packer
The totality of evidence from large-scale, randomized, controlled clinical trials and mechanistic studies in the laboratory has provided six crucial lessons about the emerging role of SGLT2 inhibitors to prevent the onset of heart failure in patients at high risk and slow the progression of heart failure in patients with established disease.
-
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-13 Ioannis Akoumianakis, Murray Polkinghorne, Charalambos Antoniades
WNT signalling comprises a diverse spectrum of receptor-mediated pathways activated by a large family of WNT ligands and influencing fundamental biological processes. WNT signalling includes the β-catenin canonical pathway and the non-canonical pathways, namely the planar cell polarity and the calcium-dependent pathways. Advances over the past decade have linked non-canonical WNT signalling with key
-
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-13 Davide Capodanno, Usman Baber, Deepak L. Bhatt, Jean-Philippe Collet, George Dangas, Francesco Franchi, C. Michael Gibson, Hyeon-Cheol Gwon, Adnan Kastrati, Takeshi Kimura, Pedro A. Lemos, Renato D. Lopes, Roxana Mehran, Michelle L. O’Donoghue, Sunil V. Rao, Fabiana Rollini, Patrick W. Serruys, Philippe G. Steg, Robert F. Storey, Marco Valgimigli, Pascal Vranckx, Hirotoshi Watanabe, Stephan Windecker
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this paradigm by testing the efficacy and safety of P2Y12 inhibitor monotherapy (that is, without aspirin)
-
Shaping the future of cardiovascular medicine in the new era of wearable devices Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-09 Sinje Gehr, Christoph Russmann
Wearable devices are widely used and have a high level of societal acceptance, opening unimagined and unexploited possibilities in cardiovascular medicine. In this Clinical Outlook, we highlight the disruptive potential of wearables for cardiovascular disease prevention, diagnosis and management, and suggest strategies for quickly and safely translating these lifestyle products into medical devices
-
Climate change and cardiovascular disease: implications for global health Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-07 Haitham Khraishah, Barrak Alahmad, Robert L. Ostergard, Abdelrahman AlAshqar, Mazen Albaghdadi, Nirupama Vellanki, Mohammed M. Chowdhury, Sadeer G. Al-Kindi, Antonella Zanobetti, Antonio Gasparrini, Sanjay Rajagopalan
Climate change is the greatest existential challenge to planetary and human health and is dictated by a shift in the Earth’s weather and air conditions owing to anthropogenic activity. Climate change has resulted not only in extreme temperatures, but also in an increase in the frequency of droughts, wildfires, dust storms, coastal flooding, storm surges and hurricanes, as well as multiple compound
-
The ongoing quest for the first total artificial heart as destination therapy Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-06-06 Annemijn Vis, Maziar Arfaee, Husain Khambati, Mark S. Slaughter, Jan F. Gummert, Johannes T. B. Overvelde, Jolanda Kluin
Many patients with end-stage heart disease die because of the scarcity of donor hearts. A total artificial heart (TAH), an implantable machine that replaces the heart, has so far been successfully used in over 1,700 patients as a temporary life-saving technology for bridging to heart transplantation. However, after more than six decades of research on TAHs, a TAH that is suitable for destination therapy
-
Invention and uptake of TAVI over the first 20 years Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-31 Alain Cribier
Transcatheter aortic valve implantation (TAVI) is a breakthrough technology to replace the aortic valve in patients with severe aortic stenosis using simple cardiac catheterization instead of thoracic surgery. Initiated 20 years ago by my colleagues and me, TAVI has been performed in >1.5 million patients globally and has profoundly altered the landscape of cardiovascular medicine.
-
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease. Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-30 Donato Santovito,Christian Weber
-
Selective JAG1–NOTCH3 targeting shows potential for treating PAH Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-27 Irene Fernández-Ruiz
Different Notch ligands have opposing roles in regulating the proliferation and differentiation of vascular smooth muscle cells in the pulmonary vasculature in pulmonary arterial hypertension. Selectively targeting Jagged 1–NOTCH3 signalling might be an effective and safe strategy for the treatment of this condition.
-
Mediterranean diet superior to low-fat diet for secondary prevention of CVD Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-27 Gregory B. Lim
Dietary interventions can reduce the risk of cardiovascular events. According to the CORDIOPREV study, a Mediterranean-style diet is superior to a low-fat diet in preventing major cardiovascular events in patients with cardiovascular disease.
-
Influenza replication drives cardiac dysfunction Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-27 Karina Huynh
A new study demonstrates that direct infection of cardiomyocytes is required to induce the cardiovascular effects of influenza virus infection.
-
A single hs-cTnT test to exclude AMI. Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-01 Karina Huynh
-
Use of HF risk score to improve trial efficiency. Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-01 Karina Huynh
-
BP management with a village-doctor-led strategy. Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-07-01 Karina Huynh
-
Repurposing drugs to treat cardiovascular disease in the era of precision medicine Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-23 Mena Abdelsayed, Eric J. Kort, Stefan Jovinge, Mark Mercola
Drug repurposing is the use of a given therapeutic agent for indications other than that for which it was originally designed or intended. The concept is appealing because of potentially lower development costs and shorter timelines than are needed to produce a new drug. To date, drug repurposing for cardiovascular indications has been opportunistic and driven by knowledge of disease mechanisms or
-
Caffeine consumption and cardiovascular health Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-17 Rob M. van Dam, Frank B. Hu
Moderate coffee consumption (2–5 cups per day) has been consistently associated with a lower risk of cardiovascular disease in epidemiological studies. For most individuals, a caffeine intake of up to 400 mg per day is safe and moderate coffee consumption can be included as part of a healthy lifestyle.
-
CNR1 antagonism attenuates cannabis-induced atherosclerosis Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-17 Karina Huynh
The soybean flavonoid genistein can attenuate cannabis-induced inflammation, oxidative stress and atherosclerosis by binding to and inhibiting cannabinoid receptor 1.
-
The need for increased pragmatism in cardiovascular clinical trials Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-17 Muhammad Shariq Usman, Harriette G. C. Van Spall, Stephen J. Greene, Ambarish Pandey, Darren K. McGuire, Ziad A. Ali, Robert J. Mentz, Gregg C. Fonarow, John A. Spertus, Stefan D. Anker, Javed Butler, Stefan K. James, Muhammad Shahzeb Khan
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in selected patient populations under explicitly protocol-defined settings. Although these ‘explanatory’ trial designs optimize conditions to test the efficacy and safety of an intervention, they limit the generalizability of trial findings in broader clinical settings. The concept of ‘pragmatism’ in RCTs addresses
-
Neuroimmune–arterial interfaces regulate atherosclerosis progression Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-16 Gregory B. Lim
The adventitia of atherosclerotic arteries is innervated by efferent and afferent neurons that form neuroimmune cardiovascular interfaces and modulate disease progression; ablating the sympathetic innervation to these regions is a potential therapeutic strategy.
-
A roadmap of strategies to support cardiovascular researchers: from policy to practice Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-16 Niamh Chapman, Emma E. Thomas, Joanne T. M. Tan, Sally C. Inglis, Jason H. Y. Wu, Rachel E. Climie, Dean S. Picone, Lauren C. Blekkenhorst, Steven G. Wise, Katrina M. Mirabito Colafella, Anna C. Calkin, Francine Z. Marques
Cardiovascular disease remains the leading cause of death worldwide. Cardiovascular research has therefore never been more crucial. Cardiovascular researchers must be provided with a research environment that enables them to perform at their highest level, maximizing their opportunities to work effectively with key stakeholders to address this global issue. At present, cardiovascular researchers face
-
The role of mitochondrial fission in cardiovascular health and disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-06 Justin M. Quiles, Åsa B. Gustafsson
Mitochondria are organelles involved in the regulation of various important cellular processes, ranging from ATP generation to immune activation. A healthy mitochondrial network is essential for cardiovascular function and adaptation to pathological stressors. Mitochondria undergo fission or fusion in response to various environmental cues, and these dynamic changes are vital for mitochondrial function
-
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-05-06 Anthony Wong, Homaira Hamidzada, Slava Epelman
Cardioimmunology is a field that encompasses the immune cells and pathways that modulate cardiac function in homeostasis and regulate the temporal balance between tissue injury and repair in disease. Over the past two decades, genetic fate mapping and high-dimensional sequencing techniques have defined increasing functional heterogeneity of innate and adaptive immune cell populations in the heart and
-
Targeted therapies for cardiac diseases Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-25 Christoph Maack, Jil C. Tardiff
Heart failure is a systemic disease in which neuroendocrine activation, inflammation and metabolic changes can impair cardiac function. In addition, variants in genes encoding sarcomeric proteins can predispose individuals to develop heart failure. The 2022 Gordon Research Conference on Cardiac Regulatory Mechanisms aims to identify novel treatment targets by applying high-resolution approaches to
-
Novel lipid-lowering therapies targeting ANGPTL3 and Lp(a) Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-21 Gregory B. Lim
The results of two early-phase trials of novel lipid-lowering agents targeting ANGPTL3 and lipoprotein(a) might help to combat the residual risk of cardiovascular events in patients treated with statins and/or PCSK9 inhibitors to lower LDL-cholesterol levels.
-
Optical coherence tomography in coronary atherosclerosis assessment and intervention Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-21 Makoto Araki, Seung-Jung Park, Harold L. Dauerman, Shiro Uemura, Jung-Sun Kim, Carlo Di Mario, Thomas W. Johnson, Giulio Guagliumi, Adnan Kastrati, Michael Joner, Niels Ramsing Holm, Fernando Alfonso, William Wijns, Tom Adriaenssens, Holger Nef, Gilles Rioufol, Nicolas Amabile, Geraud Souteyrand, Nicolas Meneveau, Edouard Gerbaud, Maksymilian P. Opolski, Nieves Gonzalo, Guillermo J. Tearney, Brett
Since optical coherence tomography (OCT) was first performed in humans two decades ago, this imaging modality has been widely adopted in research on coronary atherosclerosis and adopted clinically for the optimization of percutaneous coronary intervention. In the past 10 years, substantial advances have been made in the understanding of in vivo vascular biology using OCT. Identification by OCT of culprit
-
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-20 Gregory B. Lim
In patients with atrial fibrillation, treatment with asundexian, a novel, oral, small-molecule inhibitor of coagulation factor XIa, reduces the incidence of bleeding compared with standard dosing with the factor Xa inhibitor apixaban.
-
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-20 Karina Huynh
A strategy of treating mild chronic hypertension in pregnant women using a blood pressure target of <140/90 mmHg reduces the risk of pre-eclampsia and does not increase the risk of poor fetal growth or fetal death.
-
Electronic alerts can PROMPT guideline-directed care for HFrEF Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-20 Karina Huynh
In the PROMPT-HF trial, alerts embedded within electronic health records that contained guideline-directed recommendations for patients with heart failure improved the prescription of guideline-directed medical therapy.
-
Menopausal hormone therapy does not lower Lp(a)-associated CHD risk Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-20 Irene Fernández-Ruiz
Use of hormone-replacement therapy (HRT) for menopausal symptoms is associated with a modest reduction in plasma lipoprotein(a) (Lp(a)) levels but is not associated with a lower Lp(a)-associated risk of coronary heart disease compared with no HRT use, according to findings presented at ACC.22.
-
A proteomic model shows potential as a surrogate end point for CVD risk Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-20 Irene Fernández-Ruiz
A model generated using proteomics and machine learning that included 27 proteins was able to predict the 4-year risk of myocardial infarction, heart failure, stroke or all-cause death better than a clinical model and was sensitive to the adverse and beneficial changes in outcome.
-
Childhood cardiovascular risk factors lead to heart disease in adults Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-19 Karina Huynh
A prospective cohort study is the first to show a direct link between childhood cardiovascular risk factors and cardiovascular events in adults.
-
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-19 Anja Karlstaedt, Javid Moslehi, Rudolf A. de Boer
Cardiovascular disease and cancer are the two leading causes of morbidity and mortality in the world. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation
-
The microtubule cytoskeleton in cardiac mechanics and heart failure Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-19 Matthew A. Caporizzo, Benjamin L. Prosser
The microtubule network of cardiac muscle cells has unique architectural and biophysical features to accommodate the demands of the working heart. Advances in live-cell imaging and in deciphering the ‘tubulin code’ have shone new light on this cytoskeletal network and its role in heart failure. Microtubule-based transport orchestrates the growth and maintenance of the contractile apparatus through
-
The dynamic cardiac cellular landscape: visualization by molecular imaging Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-19 Kory J. Lavine, Yongjian Liu
Paradigm-shifting studies have revealed that the heart contains heterogeneous and dynamic immune and stromal cell populations that are crucial determinants of health and disease. Advances in molecular imaging now make it possible to non-invasively visualize the cardiac cellular landscape in humans, providing a means to guide precision therapies.
-
Blood pressure and its variability: classic and novel measurement techniques Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-19 Aletta E. Schutte, Anastasios Kollias, George S. Stergiou
Current hypertension guidelines recommend using the average values of several blood pressure (BP) readings obtained both in and out of the office for the diagnosis and management of hypertension. In-office BP measurement using an upper-arm cuff constitutes the evidence-based reference method for current BP classification and treatment targets. However, out-of-office BP evaluation using 24 h ambulatory
-
Alirocumab induces plaque regression Nat. Rev. Cardiol. (IF 49.421) Pub Date : 2022-04-14 Irene Fernández-Ruiz
In patients with acute myocardial infarction, the addition of the PCSK9 inhibitor alirocumab to high-intensity statin therapy leads to a greater regression of atherosclerotic plaques in non-infarct-related arteries after 52 weeks than statin therapy alone, according to findings from the PACMAN-AMI trial.